When a patient relapsed after years of treatment and a stem cell transplant, Kevin McNerney, M.D., could feel hope dwindling. The odds his patient would live to adulthood were now just 1 in 5.With few options remaining, the young leukemia patient and his family opted to take part in a clinical trial, a one-time immunotherapy infusion that included a synthetic receptor designed to identify cancer cells, enabling the body’s immune system to target and kill them…
Read the full article here.
